- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT03081390
Migräne- und CVD-Risiko bei Frauen
Mechanismen des erhöhten Risikos für Herz-Kreislauf-Erkrankungen bei Frauen mit Migräne
The primary goal of this study is to test the effects of a high-fat, high-carbohydrate mixed meal on candidate modulators of cardiovascular disease risk (inflammation, vascular reactivity, sympathetic nervous system tone, and response to pain) in young adult women with migraine compared with healthy young women. This is study enrolling both cases (women with migraine) and controls (women without migraine), with equal numbers of normal weight and obese women in each group. Participants will undergo a telephone screening and a single day in-person study visit.
Studienübersicht
Status
Bedingungen
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19004
- University of Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
- Children's Hospital of Philadelphia
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria (all):
- Female 18-35 years of age, inclusive
- BMI 18.5-24.9 kg/m2, inclusive
- BMI ≥30 kg/m2
Inclusion Criteria (cases only):
- Diagnosis of migraine per ICHD-3-beta (1-10 migraine days per month)
Exclusion Criteria (all):
- Smoking (current or former)
- Chronic use of medications, including oral contraceptives
- Major medical or psychiatry illness (e.g. diabetes, fibromyalgia, major depression/anxiety)
- Pregnant or nursing
- Allergies or sensitivity to any of the ingredients of the meal
- Inability to fast for 10 hours and/or abstain from caffeine intake for 24 hours
- Treatment with antibiotics or steroids within the previous 3 months
- Treatment with NSAIDs within the previous 1 week
Exclusion Criteria (controls only):
- Migraine headaches, or headaches other than tension-type headaches with a frequency of 1 or fewer days per month
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Sonstiges
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: No migraine, normal weight
|
An intravenous catheter is placed for serial blood draws for inflammatory markers and ancillary studies. The participant consumes a test meal, and measurements are made for 4 hours. Skin conductance will be monitored continuously with 2 electrodes placed on the plantar surface of the foot. To induce pain, we will use the cold pressor test. Participants submerge one hand in a bath with iced water (2-4ºC) for 2 minutes. Blood pressure and heart rate are monitored every minute starting 5 minutes before the cold pressor test and for 10 minutes after the participant withdraws the hand from the bath. This testing will be performed at baseline and post-meal. At baseline and post-meal, we will assess flow-mediated dilation at the brachial artery using well-validated ultrasound techniques. |
|
Experimental: No migraine, obese
|
An intravenous catheter is placed for serial blood draws for inflammatory markers and ancillary studies. The participant consumes a test meal, and measurements are made for 4 hours. Skin conductance will be monitored continuously with 2 electrodes placed on the plantar surface of the foot. To induce pain, we will use the cold pressor test. Participants submerge one hand in a bath with iced water (2-4ºC) for 2 minutes. Blood pressure and heart rate are monitored every minute starting 5 minutes before the cold pressor test and for 10 minutes after the participant withdraws the hand from the bath. This testing will be performed at baseline and post-meal. At baseline and post-meal, we will assess flow-mediated dilation at the brachial artery using well-validated ultrasound techniques. |
|
Experimental: Migraine, normal weight
|
An intravenous catheter is placed for serial blood draws for inflammatory markers and ancillary studies. The participant consumes a test meal, and measurements are made for 4 hours. Skin conductance will be monitored continuously with 2 electrodes placed on the plantar surface of the foot. To induce pain, we will use the cold pressor test. Participants submerge one hand in a bath with iced water (2-4ºC) for 2 minutes. Blood pressure and heart rate are monitored every minute starting 5 minutes before the cold pressor test and for 10 minutes after the participant withdraws the hand from the bath. This testing will be performed at baseline and post-meal. At baseline and post-meal, we will assess flow-mediated dilation at the brachial artery using well-validated ultrasound techniques. |
|
Experimental: Migraine, obese
|
An intravenous catheter is placed for serial blood draws for inflammatory markers and ancillary studies. The participant consumes a test meal, and measurements are made for 4 hours. Skin conductance will be monitored continuously with 2 electrodes placed on the plantar surface of the foot. To induce pain, we will use the cold pressor test. Participants submerge one hand in a bath with iced water (2-4ºC) for 2 minutes. Blood pressure and heart rate are monitored every minute starting 5 minutes before the cold pressor test and for 10 minutes after the participant withdraws the hand from the bath. This testing will be performed at baseline and post-meal. At baseline and post-meal, we will assess flow-mediated dilation at the brachial artery using well-validated ultrasound techniques. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
LPS area under the curve (AUC)
Zeitfenster: LPS is measured at baseline every 30 minutes for 4 hours.
|
The primary study endpoint is lipopolysaccharide (LPS) area under the curve (AUC) during MMTT. |
LPS is measured at baseline every 30 minutes for 4 hours.
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Flow-mediated dilation (FMD)
Zeitfenster: FMD is measured at baseline and 2.5 hours after MMTT.
|
Vascular reactivity via brachial artery ultrasound, expressed as flow-mediated dilation (% of baseline diameter, normalized). |
FMD is measured at baseline and 2.5 hours after MMTT.
|
|
Sympathetic tone at rest and with painful stimulus
Zeitfenster: Sympathetic tone at rest and with painful stimulus are measured at baseline and 3 hours after MMTT.
|
Sympathetic tone via skin conductance is expressed as mean skin conductance level (SCL) in microsiemens, and assessed at rest and following a pain stimulus (cold pressor test). |
Sympathetic tone at rest and with painful stimulus are measured at baseline and 3 hours after MMTT.
|
Mitarbeiter und Ermittler
Sponsor
Ermittler
- Hauptermittler: Shana E McCormack, MD, Children's Hospital of Philadelphia
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 826251
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
After the primary publication is complete, interested investigators can request these data without identifiers. The study team will evaluate the request for scientific rigor and ensure consistency with our protocol, and then provide data without identifiers via secure file-share. This will include the subset of participants who indicated their data could be used for ancillary and/or future studies.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .